

1-27-2019

## Workshop Agenda

Fernanda Masri

Follow this and additional works at: [http://dc.engconfintl.org/cell\\_gene\\_therapies\\_vi](http://dc.engconfintl.org/cell_gene_therapies_vi)

 Part of the [Biomedical Engineering and Bioengineering Commons](#)

---

# Developing a toolkit to engineer viral vector manufacturing and next generation gene therapies

## Final Agenda:

9.00-9.30 **Registration and coffee**

---

9.30-12.45 **Session 1: *Challenges and potential solutions for processing of viral vectors***

9.30-10.00 Viral Vector workflow overview: From construct to USP to DSP

*Anandita Seth, Head of Research and Technology, Viral Therapy, Lonza*

10.00-10.30 Insights into adeno-associated virus processing

*Hanna Lesch, Gene Therapy Unit Director, Kuopio Centre for Gene & Cell Therapy (KCT)*

10.30-11.00 Scaling up lentiviral vector production from Cell Factories to disposable bioreactor: development and optimization of upstream and downstream process steps

*Luca Crippa, Downstream Vector Development Supervisor, MolMed*

---

11.00-11.20 **Coffee break**

---

11.20-12.50 **Activity:** Assessing the impact of process related decisions on manufacturability of viral vectors

---

12.50-13.30 **Lunch & Networking**

---

13.30-16.50 **Session 2: *Next generation gene therapies: Continuous bioprocessing***

13.30-14.00 Continuous bioprocessing for viral vectors -upstream processing

*Sven Ansorge, Research Officer, National Research Council Canada*

14.00-14.20 Technology Transfer of Cell and Gene Therapy Products into a new GMP Facility : Success Factors and Key Challenges

*LiYing Yang, Head of MSAT, Lonza*

14.20-16.10 **Activity:** In groups join the discussion with your table lead. Table leads are:

1. *Damian Marshall, Director of New and Enabling Technologies, CGT Catapult*
2. *Peter Jones, Head of Operational Strategy, Oxford Biomedica*
3. *David Pollard, Head of New Materials & Components, Sartorius Stedim*
4. *Sven Ansorge, Research Officer, National Research Council Canada*
5. *LiYing Yang, Head of MSAT, Lonza*
6. *Luca Crippa, Downstream Vector Development Supervisor, MolMed*
7. *Hanna Lesch, Gene Therapy Unit Director, Kuopio Centre for Gene and Cell Therapy (KCT)*

16.10-16.50 Conclusions from the discussions

---

16.50-17.00 **Wrap-up and closure**